Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination

Intern Med. 2017;56(8):921-923. doi: 10.2169/internalmedicine.56.7783. Epub 2017 Apr 15.

Abstract

Nanoparticle albumin-bound (nab)-paclitaxel has shown promising activity in advanced gastric cancer treatment. We herein report a case of advanced gastric cancer involving long-term management with a single administration of nab-paclitaxel. A 71-year-old man diagnosed with advanced gastric cancer with malignant ascites was treated with nab-paclitaxel as a second-line chemotherapy. He refused treatment continuation because of various severe toxicities in the first treatment cycle; he was therefore followed-up without any further treatments. Despite this, no disease progression was observed over 9 months. After progression, he received dose-dense paclitaxel, but he did not respond to this treatment and eventually died.

Keywords: ascites; dissemination; gastric cancer; nab-paclitaxel.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Albumins / administration & dosage*
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Drug Delivery Systems / methods
  • Fatal Outcome
  • Humans
  • Male
  • Nanoparticles / administration & dosage
  • Paclitaxel / administration & dosage*
  • Peritoneal Neoplasms / drug therapy*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Antineoplastic Agents, Phytogenic
  • Paclitaxel